Boehringer Ingelheim International GmbH Sustainability Profile
Boehringer Ingelheim International GmbH, a leading global pharmaceutical company, is headquartered in Ingelheim am Rhein, Germany. Founded in 1885, the company has established a strong presence in the healthcare industry, focusing on human pharmaceuticals, animal health, and biopharmaceutical contract manufacturing. With a commitment to innovation, Boehringer Ingelheim is renowned for its core products, including prescription medications for respiratory diseases, cardiovascular conditions, and diabetes management. The company’s unique approach to research and development has positioned it as a key player in the market, consistently delivering groundbreaking therapies. Notable achievements include significant advancements in veterinary medicine and a robust pipeline of new treatments, reinforcing its status as one of the top pharmaceutical firms globally. Boehringer Ingelheim continues to prioritise improving patient outcomes and animal health through its dedicated efforts in scientific excellence.
DitchCarbon Score
How does Boehringer Ingelheim International GmbH's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Boehringer Ingelheim International GmbH's score of 20 is lower than 84% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Boehringer Ingelheim International GmbH, headquartered in Germany (DE), currently does not provide specific carbon emissions data, as indicated by the absence of reported figures. The company has not outlined any documented reduction targets or commitments to climate initiatives, such as those from the Science Based Targets initiative (SBTi) or other industry-standard frameworks. As a current subsidiary of a larger corporate family, Boehringer Ingelheim's climate commitments and emissions data may be influenced by its parent organisation. However, no specific cascading data or targets have been identified from the parent company. In the context of the pharmaceutical industry, companies are increasingly expected to adopt robust climate strategies and transparent reporting practices. While Boehringer Ingelheim has not yet disclosed its emissions or reduction initiatives, the industry trend suggests a growing emphasis on sustainability and carbon footprint reduction.
How Carbon Intensive is Boehringer Ingelheim International GmbH's Industry?
How Carbon Intensive is Boehringer Ingelheim International GmbH's Location?
Boehringer Ingelheim International GmbH's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Boehringer Ingelheim International GmbH has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
